Clinical trials: Soft Tissue Infections
Kaposi's Sarcoma
Assessment of Blood Vessel Density in Kaposi's Sarcoma Lesions
The purpose of this study is to develop imaging techniques to determine the density of blood vessels and the amount of blood flow in Kaposi s sarcoma (KS) tumors.
- Trial name
- NCT00026793
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- National Cancer Institute (NCI)
Bacteremia, Soft Tissue Infections
Safety, Efficacy, and Pharmacokinetics (PK) of Daptomycin (MK-3009) in Japanese Pediatric Subjects With Complicated Skin and Soft Tissue Infections (cSSTI) and Bacteremia (MK-3009-029)
The purpose of this study is to assess the safety, efficacy and pharmacokinetic (PK) parameters of daptomycin for injection in Japanese pediatric participants aged 1 to 17 years with complicated skin and soft tissue infection…
- Conditions
- Bacteremia, Soft Tissue Infections, Skin Diseases, Infectious
- Trial name
- NCT03643952
- Testing
- Daptomycin for Injection
- Where
- 16 sites in Japan
- Volunteers
- 18 people
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Infections, Skin Structures and Soft Tissue Infections
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
The purpose of this study is to evaluate the safety and efficacy of omadacycline as compared to linezolid in the treatment of adults with acute bacterial skin and skin structure infections.
- Trial name
- NCT02877927
- Testing
- Omadacycline, Linezolid
- Where
- 50 sites in United States
- Volunteers
- 735 people
- Sponsor
- Paratek Pharmaceuticals Inc
Kaposi´s Sarcoma
Intralesional Bevacizumab for Treating AIDS-associated Kaposi´s Sarcoma of the Larynx, Pharynx and Oral Cavity
Kaposi sarcoma remains the most common malignancy among persons with HIV. Lesions localized to the airway may cause bleeding, pain and dyspnea. New therapeutic approaches for local disease are needed.
- Trial name
- NCT01296815
- Testing
- Bevacizumab
- Where
- Mexico
- Volunteers
- 14 people
- Sponsor
- Centro de Investigación en. Enfermedades Infecciosas, Mexico
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)
Staphylococcal Infection
Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
The purpose of this clinical trial is to evaluate 2 different antibiotics, drugs that fight bacteria, [clindamycin (CLINDA) and trimethoprim-sulfamethoxazole (TMP-SMX)] and wound care for the outpatient management of…
- Trial name
- NCT00730028
- Testing
- Trimethoprim-sulfamethoxazole, Clindamycin
- Where
- 6 sites in United States
- Volunteers
- 1,310 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Castleman Disease, Multicentric Castleman Disease
Tocilizumab for KSHV-Associated Multicentric Castleman Disease
Background: Kaposi's sarcoma-associated herpes virus (KSHV)-associated multicentric Castleman disease (KSHV-MCD) is caused by a herpes virus known as KSHV.
- Conditions
- Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
- Trial name
- NCT01441063
- Testing
- Zidovudine, Tocilizumab, Valganciclovir (VGC)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi Sarcoma, HIV Infections
An Evaluation of Tc 99m Tilmanocept by Intravenous (IV) and Subcutaneous (SC) Injection in Kaposi Sarcoma (KS)
To determine the safety of escalating IV doses of Tc 99m tilmanocept in HIV (human immunodeficiency virus) subjects with confirmed KS and to compare results obtained from subcutaneous and IV administrations of Tc 99m tilmanocept…
- Trial name
- NCT03157167
- Testing
- Tc99m-tilmanocept
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Navidea Biopharmaceuticals
Third Degree Burn, Burns
StrataGraft™ Skin Tissue (Human Donor Skin) In The Surgical Management Of Complex Skin Defects
This pilot Phase I/II clinical study will be conducted at up to three clinical sites. This is an open-label, randomized, comparative study with a maximum of fifteen (15) patients, each with skin defects.
- Conditions
- Third Degree Burn, Burns, Wound Infection, Degloving Injury
- Trial name
- NCT00618839
- Testing
- StrataGraft Skin Tissue, Cadaver allograft
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Stratatech, a Mallinckrodt Company
HIV-1 Infection, Kaposi's Sarcoma
Antiretroviral Therapy (ART) Alone or With Delayed Chemo Versus ART With Immediate Chemo for Limited AIDS-related Kaposi's Sarcoma
AIDS-related Kaposi's sarcoma (AIDS-KS) occurs in persons with HIV infection who are also infected with the Kaposi's sarcoma herpesvirus (KSHV).
- Trial name
- REACT-KS (NCT01352117)
- Testing
- efavirenz/emtricitabine/tenofovir disoproxil fumarate, etoposide
- Where
- 8 sites in Brazil, Kenya and 4 more
- Volunteers
- 192 people
- Sponsor
- Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Endovascular Infection, Bone and Joint Infection
Comparing Oral Versus Parenteral Antimicrobial Therapy
This is an investigator initiated multisite pragmatic randomized controlled trial designed to demonstrate equivalent effectiveness with improved safety of early transition from intravenous (IV) antimicrobial therapy to complex…
- Conditions
- Endovascular Infection, Bone and Joint Infection, Skin and Soft Tissue Infection, Pulmonary Infection
- Trial name
- COPAT (NCT05977868)
- Testing
- Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- West Virginia University
Bone Graft; Complications, Infection or Inflammation, Ridge Deficency
To Compare Different Soft Tissue Grafts at the Time of Lateral Ridge Augmentation Procedure.
This study will compare two commonly used soft tissue grafting techniques (connective tissue graft, CTG vs Acellular Dermal Matrix, ADM) to augment the soft tissue at the time of lateral ridge augmentation procedure.
- Conditions
- Bone Graft; Complications, Infection or Inflammation, Ridge Deficency, Dental Implant
- Trial name
- NCT03774888
- Testing
- Connective tissue graft at time of bone graft, Acellular Demal Matrix at time of bone graft, No soft tissue grafting at time of bone graft
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- University of Alabama at Birmingham
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Skin Structures and Soft Tissue Infections
Phase 3 Study to Evaluate Safety and Efficacy of Iclaprim Versus Vancomycin for ABSSSI: REVIVE-2
This is a multicenter, randomized, double-blind study of the efficacy and safety of iclaprim compared to vancomycin for the treatment of skin and skin structure infections.
- Trial name
- REVIVE-2 (NCT02607618)
- Testing
- Iclaprim, Vancomycin
- Where
- 54 sites in United States, Argentina and 8 more
- Volunteers
- 613 people
- Sponsor
- Motif Bio
Skin Diseases, Infectious, Soft Tissue Infections
Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections
This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections
- Trial name
- NCT00430937
- Testing
- Daptomycin, Vancomycin, Teicoplanin
- Volunteers
- 194 people
- Sponsor
- Novartis Pharmaceuticals
Recurrent Kaposi Sarcoma, Skin Kaposi Sarcoma
Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma
This pilot phase II trial studies how well nelfinavir mesylate works in treating patients with kaposi sarcoma. Nelfinavir mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT03077451
- Testing
- Laboratory Biomarker Analysis, Nelfinavir Mesylate
- Where
- 12 sites in United States, South Africa and 1 more
- Volunteers
- 36 people
- Sponsor
- AIDS Malignancy Consortium
Kaposi's Sarcoma, HIV Positive
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
- Conditions
- Kaposi's Sarcoma, HIV Positive, AIDS
- Trial name
- NCT02029430
- Testing
- 50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- ImmunityBio, Inc.
Skin and Soft Tissue Infections
Evaluating the Use of Large-dose, Extended Interval Vancomycin Intravenous Administration for Skin and Soft Tissue Infections
Our hypothesis is that large-dose, extended-interval vancomycin (30 mg/kg IV q24h) administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin (15 mg/kg IV q12h) administration for…
- Trial name
- VOD (NCT01037192)
- Testing
- vancomycin
- Where
- Canada
- Volunteers
- 4 people
- Sponsor
- Fraser Health
SARS-CoV Infection, COVID-19
COVID19 SARS Vaccinations: Systemic Allergic Reactions to SARS-CoV-2 Vaccinations
Background: Allergic reactions have been reported to occur after vaccination with both the Pfizer-BioNTech COVID-19 Vaccine and Moderna COVID-19 Vaccine.
- Conditions
- SARS-CoV Infection, COVID-19, Allergic Reaction, Mast Cell Disorder
- Trial name
- SARS (NCT04761822)
- Testing
- Moderna COVID-19 Vaccine, Pfizer-BioNTech COVID-19 Vaccine
- Where
- 29 sites in United States
- Volunteers
- 746 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Skin Diseases, Infectious, Skin Diseases, Bacterial
Study of Tedizolid Phosphate in Adolescents With Complicated Skin and Soft Tissue Infection (cSSTI) (MK-1986-012)
The purpose of the study is to compare the safety of intravenous (IV) and/or oral 6-day 200 mg tedizolid phosphate with 10-day comparator in participants 12 to <18 years with cSSTI.
- Trial name
- NCT02276482
- Testing
- Tedizolid Phophate, Antibiotic comparator, Aztreonam
- Volunteers
- 120 people
- Sponsor
- Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)